Advertisement
Canada markets open in 28 minutes

  • S&P/TSX

    21,740.20
    -159.79 (-0.73%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CAD/USD

    0.7235
    -0.0018 (-0.25%)
     

  • CRUDE OIL

    84.90
    -0.51 (-0.60%)
     

  • Bitcoin CAD

    87,246.79
    -4,121.80 (-4.51%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,390.60
    +7.60 (+0.32%)
     

  • RUSSELL 2000

    1,975.71
    -27.47 (-1.37%)
     

  • 10-Yr Bond

    4.6300
    +0.0020 (+0.04%)
     

  • NASDAQ futures

    17,900.75
    +24.50 (+0.14%)
     

  • VOLATILITY

    18.40
    -0.83 (-4.31%)
     

  • FTSE

    7,866.24
    -99.29 (-1.25%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6800
    -0.0024 (-0.35%)
     
BREAKING:

INFLATION IN CANADA UP SLIGHTLY TO 2.9% IN MARCH

On a seasonally adjusted monthly basis, the CPI increased 0.3% last month, says StatCan

NVAX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 11, 2022 in the Class Action Filed on Behalf of Novavax, Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 29, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Novavax, Inc. (NASDAQ: NVAX) alleging that the Company violated federal securities laws.

Class Period: March 2, 2021 to October 19, 2021
Lead Plaintiff Deadline: January 11, 2022
No obligation or cost to you.

Learn more about your recoverable losses in NVAX:
https://www.kleinstocklaw.com/pslra-1/novavax-inc-loss-submission-form-2?id=21647&from=5

Novavax, Inc. NEWS - NVAX NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Novavax, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373, a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 coronavirus; (ii) as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization regulatory timelines for NVX-CoV2373; (iii) accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Novavax you have until January 11, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Novavax securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the NVAX lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105548